Ingelheim/Vienna, 11 July 2006 – At the Congress of the Federation of European Neuroscience Societies (FENS) taking place from July 8-12, 2006, in Vienna, the Boehringer Ingelheim FENS Research Award which is endowed with 25 000 Euro was presented for the third time. The sponsor, Boehringer Ingelheim, donates the award to young European scientists for exceptional research in the field of neurosciences.
37 year-old Dr Zoltan Nusser from the Institute of Experimental Medicine in Budapest, Hungary, received this year’s Boehringer Ingelheim FENS Research Award for his outstanding studies on mechanisms of synaptic neurotransmission.
"It is a great honour for me to receive this award. I deeply appreciate the recognition of our scientific progress" said Dr Nusser, who currently conducts basic research at the Laboratory of Cellular Neurophysiology of the Institute of Experimental Medicine in Budapest, Hungary. "The results of our research contribute to a better understanding of synaptic neurotransmission with special reference to the role of ligand- and voltage-gated ion-channels in this process”, he added.
Through his pioneering work in the area of synaptic transmission and the study of ion channels, Dr. Zoltan Nusser has significantly impacted on European neuroscience research . His work serves as impressive proof that combined neuroanatomical, electrophysiological and modelling approaches are ideally suited to study the mechanisms underlying neuronal communication between nerve cells in health and disease state.
"We appreciate that – for the third time - Boehringer Ingelheim can offer the FENS Research Award and is in the position to support the advancement of young scientists," says Dr Barner, Vice-Chairman of the Board, Corporate Board Division Pharma Research, Development and Medicine at Boehringer Ingelheim.
"We are glad to be able to again demonstrate Boehringer Ingelheim’s commitment to basic research in the area of neuroscience since this is a prerequisite for progress in the efforts to discover new treatment options for patients suffering from devastating diseases of the nervous system”, said Dr. Bernd Sommer, Head of Boehringer Ingelheim’s Department of CNS Diseases Research, who presented the prize to Dr. Nusser.
The speech in Dr Nusser’s honour was delivered by Professor Tamas Freund, President of the Federation of European Neuroscience Societies (FENS).
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost
37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.